Dr. Reddy’s Laboratories launches Pregabalin Capsules in US Market

30 Jul 2019 Evaluate

Dr. Reddy’s Laboratories has launched Pregabalin Capsules a therapeutic equivalent generic version of Lyrica (pregabalin) capsules approved by the U.S. Food and Drug Administration (USFDA). The Lyrica (pregabalin) Capsules brand had U.S. sales of approximately $5,462 million MAT for the most recent twelve months ending in May 2019 according to IQVIA Health.

The company’s Pregabalin Capsules are available in 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg capsules in bottle count sizes of 90. This is also a controlled substance schedule V product. Lyrica is a trademark of C.P. Pharmaceuticals International C.V.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1218.40 9.95 (0.82%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×